标题
Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF UROLOGY
Volume 19, Issue 7, Pages 594-601
出版商
Wiley
发表日期
2012-03-15
DOI
10.1111/j.1442-2042.2012.02997.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pathways of chemotherapy resistance in castration-resistant prostate cancer
- (2011) K. L. Mahon et al. ENDOCRINE-RELATED CANCER
- Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix
- (2011) Matthew R. Smith et al. JOURNAL OF UROLOGY
- A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
- (2011) E. David Crawford et al. JOURNAL OF UROLOGY
- Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples
- (2010) Wolfgang Koechling et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- 140 OPEN-LABEL, EXPLORATORY STUDY OF DEGARELIX AS SECOND-LINE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER (CS27)
- (2010) K. Miller et al. EUROPEAN UROLOGY SUPPLEMENTS
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
- (2010) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients
- (2009) Guo-Wen Lin et al. ASIAN JOURNAL OF ANDROLOGY
- Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
- (2009) Fritz H. Schröder et al. BJU INTERNATIONAL
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
- (2009) Bertrand Tombal et al. EUROPEAN UROLOGY
- Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
- (2009) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer
- (2008) Hendrik Van Poppel et al. EUROPEAN UROLOGY
- A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
- (2008) Marc Gittelman et al. JOURNAL OF UROLOGY
- Will GnRH antagonists improve prostate cancer treatment?
- (2008) Ilpo Huhtaniemi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
- (2008) Hendrik van Poppel et al. UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started